Praxis Precision Medicines Yönetim
Yönetim kriter kontrolleri 4/4
Praxis Precision Medicines CEO'su Marcio De'Souza, Apr2020 tarihinde atandı, in görev süresi 6.33 yıldır. in toplam yıllık tazminatı $ 8.71M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.6% maaş ve 92.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.003% ine doğrudan sahiptir ve bu hisseler $ 273.95K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.3 yıl ve 4.8 yıldır.
Anahtar bilgiler
Marcio De'Souza
İcra Kurulu Başkanı
US$8.7m
Toplam tazminat
| CEO maaş yüzdesi | 7.57% |
| CEO görev süresi | 6.3yrs |
| CEO sahipliği | 0.003% |
| Yönetim ortalama görev süresi | 5.3yrs |
| Yönetim Kurulu ortalama görev süresi | 4.8yrs |
Son yönetim güncellemeleri
Recent updates
PRAX: Vormatrigine Trial Setbacks Will Drive Future Repricing Risk
Analysts have lifted the fair value estimate for Praxis Precision Medicines to $188 from $162, reflecting higher modeled revenue potential for its late stage epilepsy and essential tremor programs, partially offset by a higher discount rate, slightly lower profit margin assumptions, and a richer future P/E multiple. Analyst Commentary Recent Street research on Praxis Precision Medicines shows a wide spread in price targets and views, with several firms highlighting both upside scenarios around epilepsy and essential tremor assets and execution risks tied to clinical outcomes and commercialization.
PRAX: Essential Tremor Launch Prospects Will Drive Future Upside Despite Seizure Trial Uncertainty
Praxis Precision Medicines enters this Narrative Update with the analyst price target higher in absolute dollar terms, supported by research that reflects revised fair value estimates, updated discount rates, refreshed revenue and margin assumptions, and a lower future P/E multiple in response to recent trial outcomes and pipeline commentary. Analyst Commentary Recent research on Praxis Precision Medicines presents a mixed picture, with several firms adjusting price targets and updating models after clinical readouts and management commentary.Praxis: Commercial Launch Could Smash Expectations (Video)
Summary Prax is analyzed using a sum-of-parts valuation approach, focusing on its lead asset, Ulixa. Recent updates from the Goldman Sachs presentation highlight key developments ahead of Ulixa's commercial launch. I assess PRAX's strategic positioning and upcoming catalysts tied to Ulixa's market entry. The analysis emphasizes valuation implications and the significance of the Ulixa launch for PRAX's investment thesis. Read the full article on Seeking Alpha
PRAX: Late Stage Neurology Pipeline Will Drive Future Upside Potential
The analyst price target for Praxis Precision Medicines moved from $843 to $1,201, with analysts pointing to potential approvals for ulixacaltamide and relutrigine, along with ongoing interest in the broader late stage pipeline as key reasons for their updated assumptions. Analyst Commentary Recent Street research on Praxis Precision Medicines reflects a wide range of views, but several bullish analysts highlight what they see as meaningful upside tied to the company’s late stage neurology pipeline.PRAX: Vormatrigine Trial Setbacks Will Drive Future Repricing Risk
Analysts now place a $162.00 price target on Praxis Precision Medicines, adjusted from an earlier fair value estimate of about $85.76. This reflects updated views on discount rate, revenue growth potential, profit margins, and future P/E assumptions following recent trial outcomes and broader Street research.PRAX: Ulixacaltamide Tremor Opportunity Will Drive Future Upside Despite Vormatrigine Setback
Analysts have lifted their blended price target on Praxis Precision Medicines to about $618 from roughly $449, reflecting updated assumptions for ulixacaltamide's multi billion dollar sales potential in essential tremor and a lower, but still present, probability of success for vormatrigine after the POWER1 miss and POWER2 pause. Analyst Commentary Street research on Praxis Precision Medicines is split between enthusiasm for the ulixacaltamide opportunity and caution around execution risk after the POWER1 outcome for vormatrigine.Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade)
Summary Ulixacaltamide’s Phase 3 study was recommended to stop for futility, significantly lowering its chances of success in essential tremor. Investor focus shifts to the epilepsy pipeline, led by vormatrigine (focal epilepsy) and relutrigine (SCN2A/SCN8A-DEEs). Vormatrigine must differentiate from Xcopri and XEN1101 in a highly competitive focal epilepsy market. Relutrigine showed promising seizure reduction in rare pediatric epilepsies but needs confirmation in larger pivotal trials. Praxis has $400M+ cash, funding operations into 2028, with key epilepsy trial readouts expected in 2H 2025. Read the full article on Seeking AlphaPraxis Precision Medicines: Multiple Potential Drivers
Summary Praxis Precision Medicines, Inc., a promising clinical stage biopharma concern, has seen significant stock gains in the second half of 2024. Analyst firms are quite bullish on the stock, with eight firms recently issuing Buy ratings and price targets ranging from $114 to $305 per share. The company has several potential drivers with its late-stage pipeline candidates and possesses a decent balance sheet. While the stock should only be considered by aggressive investors given its recent rally, I have taken a small position in PRAX stock via covered call orders. An analysis around Praxis Precision Medicines follows in the paragraphs below. Read the full article on Seeking AlphaPraxis Precision Medicines: Great Price Movement, But Still Not Convinced
Summary Praxis Precision Medicines has shown impressive growth, but past trial failures and current risks warrant caution before investing. The lead candidate, Ulixacaltamide, is in a phase 3 trial for essential tremor, with results expected by the end of 2024. PRAX-628 shows promise for epilepsy, but the small patient cohort and competitive landscape raise concerns. Despite significant stock gains, I remain unconvinced and seek more data before making an investment decision. Read the full article on Seeking AlphaCEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$339m |
| Mar 31 2026 | n/a | n/a | -US$327m |
| Dec 31 2025 | US$9m | US$659k | -US$303m |
| Sep 30 2025 | n/a | n/a | -US$273m |
| Jun 30 2025 | n/a | n/a | -US$251m |
| Mar 31 2025 | n/a | n/a | -US$213m |
| Dec 31 2024 | US$13m | US$640k | -US$183m |
| Sep 30 2024 | n/a | n/a | -US$151m |
| Jun 30 2024 | n/a | n/a | -US$124m |
| Mar 31 2024 | n/a | n/a | -US$125m |
| Dec 31 2023 | US$2m | US$625k | -US$123m |
| Sep 30 2023 | n/a | n/a | -US$138m |
| Jun 30 2023 | n/a | n/a | -US$157m |
| Mar 31 2023 | n/a | n/a | -US$183m |
| Dec 31 2022 | US$6m | US$625k | -US$214m |
| Sep 30 2022 | n/a | n/a | -US$231m |
| Jun 30 2022 | n/a | n/a | -US$232m |
| Mar 31 2022 | n/a | n/a | -US$208m |
| Dec 31 2021 | US$11m | US$571k | -US$167m |
| Sep 30 2021 | n/a | n/a | -US$135m |
| Jun 30 2021 | n/a | n/a | -US$111m |
| Mar 31 2021 | n/a | n/a | -US$88m |
| Dec 31 2020 | US$12m | US$385k | -US$70m |
Tazminat ve Piyasa: Marcio 'nin toplam tazminatı ($USD 8.71M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 14.46M ).
Tazminat ve Kazançlar: Marcio 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Marcio De'Souza (47 yo)
Mr. Marcio Silva De'Souza M.B.A., has been President, Chief Executive Officer and Director of Praxis Precision Medicines, Inc. since April 2020. Mr. De'Souza joined the Praxis Precision Medicines, Inc. in...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 6.3yrs | US$8.71m | 0.0026% $ 274.0k | |
| CFO & Treasurer | 5.3yrs | US$3.20m | 0.033% $ 3.4m | |
| General Counsel & Secretary | 6.2yrs | US$2.84m | 0.024% $ 2.6m | |
| Co-Founder and President of Research & Development | no data | Veri yok | Veri yok | |
| Chief Operating Officer | less than a year | Veri yok | 0.024% $ 2.5m | |
| Chief Technical Operations Officer | 4.7yrs | Veri yok | Veri yok | |
| Chief People Officer | 5.7yrs | Veri yok | 0.013% $ 1.4m | |
| Chief Regulatory & Quality Officer | 5.9yrs | Veri yok | Veri yok | |
| Chief of Staff | 4.4yrs | Veri yok | Veri yok | |
| Head of Clinical Strategy | less than a year | Veri yok | Veri yok |
Deneyimli Yönetim: PRAX 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.3 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 6.3yrs | US$8.71m | 0.0026% $ 274.0k | |
| Independent Director | 9.7yrs | US$418.72k | 0.0068% $ 713.7k | |
| Independent Chairman of the Board | 5.9yrs | US$445.22k | 0.062% $ 6.5m | |
| Independent Director | 7.4yrs | US$426.22k | 0.00067% $ 70.3k | |
| Independent Director | 5.3yrs | US$416.72k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$421.22k | 0.0084% $ 878.5k | |
| Independent Director | 5.3yrs | US$412.72k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.6yrs | Veri yok | Veri yok | |
| Chairman of the Scientific Advisory Board | 3.6yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 3.6yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 3.6yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 3.6yrs | Veri yok | Veri yok |
Deneyimli Yönetim Kurulu: PRAX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.8 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/23 13:21 |
| Gün Sonu Hisse Fiyatı | 2026/08/21 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Praxis Precision Medicines, Inc. 29 Bu analistlerden 18, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Brian Skorney | Baird |
| Joel Beatty | Baird |
| null null | Baird |